Welcome to our dedicated page for Rallybio SEC filings (Ticker: RLYB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rallybio Corporation (RLYB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, clinical-stage biotechnology company focused on severe and rare diseases, Rallybio uses its Forms 10-K, 10-Q, and 8-K to report financial performance, pipeline developments, and material corporate events.
Rallybio’s filings include quarterly and annual reports that detail collaboration and license revenue, research and development expenses, general and administrative expenses, net income or loss, and cash, cash equivalents, and marketable securities. These reports also describe the status of key programs such as RLYB116, a differentiated C5 inhibitor in a confirmatory PK/PD Phase 1 study, and preclinical assets like RLYB332 for diseases of iron overload. Disclosures about discontinued programs, such as RLYB212 for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT), appear in these documents and related press releases.
Current Reports on Form 8-K provide timely updates on material events, including quarterly financial results, the sale of Rallybio’s interest in the ENPP1 inhibitor program REV102 to Recursion Pharmaceuticals, and Nasdaq listing matters. An August 2025 8-K, for example, describes the transfer of Rallybio’s listing to the Nasdaq Capital Market and the additional compliance period granted to regain the minimum bid price requirement.
On Stock Titan, these filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand changes in Rallybio’s financial position, pipeline priorities, and corporate transactions. Users can review real-time updates from EDGAR, examine historical 10-K and 10-Q reports, and track 8-K disclosures related to financing, collaborations, and listing compliance, all in one place.
Rallybio Corporation’s planned merger with Candid Therapeutics will not proceed after Candid ended their agreement and signed a Permitted Alternative Agreement with UCB S.A. Instead of completing the transaction, Rallybio is entitled to receive a $50,000,000 Parent Termination Fee from Candid under the merger terms.
Rallybio, Candid and UCB also signed a waiver on May 1, 2026 that adjusts certain notice rights, allows payment of the termination fee and expense reimbursements on the first business day after termination, and includes broad mutual releases of claims related to the merger agreements and contemplated transactions. Rallybio plans to withdraw its previously filed Form S-4 registration statement.
Rallybio Corp Schedule 13G reports that Laurion Capital Management and two co-managing members beneficially own 302,756 shares of Rallybio Common Stock, representing 5.72% of the class as of 03/31/2026. The filing states the shares are held by Laurion Funds, with shared voting and dispositive power among Laurion Capital, Benjamin A. Smith, and Janaka S. Maduraperuma. The statement clarifies that Laurion Capital Master Fund Ltd. holds more than 5% of the class and identifies the reporting persons and their business address.
The registrant Rallybio Corporation and Candid Therapeutics, Inc. have entered a Merger Agreement under which Merger Sub will merge into Candid and Rallybio will be renamed Candid Therapeutics, Inc. At the Effective Time, each share of Candid capital stock will convert into the right to receive shares of Rallybio common stock based on an assumed Exchange Ratio of 0.0716 (which assumes a 1-for-2.5 reverse stock split of Rallybio). Candid has committed to a Concurrent Financing of $505.5 million immediately prior to closing. On a pro forma, fully diluted basis (assuming the stated assumptions), pre-Merger Candid equityholders are expected to own approximately 57.55% of the combined company, Concurrent Financing investors 38.80%, and pre-Merger Rallybio equityholders 3.65%. Rallybio reports Rallybio Net Cash of approximately $35.81 million as of April 15, 2026 (approximately $39.47 million as of December 31, 2025) and expects to incur ongoing losses related to the Merger.
Johnson & Johnson and Johnson & Johnson Innovation‑JJDC, Inc. amend a Schedule 13G/A to report beneficial ownership of 152,901 shares of Rallybio Corporation common stock, representing 2.9% of the class. Percentage ownership is calculated using 5,289,675 shares outstanding as of March 6, 2026. The filing states the securities are directly owned by JJDC and that J&J may be deemed to indirectly beneficially own them; the amendment is signed April 13, 2026.
Rallybio Corporation reported that Chief Medical Officer Steven Ryder, M.D., who has served in that role since January 2019, has left the company effective immediately. His departure occurs as Rallybio pursues a pending business combination with Candid Therapeutics, Inc. under a previously announced merger agreement.
Under a new separation agreement, Dr. Ryder will receive severance payments and benefits consistent with a termination by Rallybio without cause, as outlined in his existing employment agreement. After the closing of the Candid merger and related change of control, he is entitled to additional severance owed for a without-cause termination following a change of control, reduced by the initial severance amounts already paid.
Rallybio states that Dr. Ryder’s restricted stock, stock options and other equity awards will remain outstanding and may continue to vest according to the merger agreement. These awards will remain exercisable until 90 days following the closing of the merger, providing a limited post-closing window for exercise.
Rallybio Corporation has entered into a merger agreement to acquire Candid Therapeutics, with Candid surviving as a wholly owned subsidiary and Rallybio to be renamed Candid Therapeutics, Inc. At the Effective Time, each share of Candid capital stock will convert into the right to receive approximately 0.0716 shares of Rallybio Common Stock (the Exchange Ratio), assuming a 1-for-2.5 reverse stock split and subject to adjustments.
Concurrently, Candid entered a subscription agreement for a $505.5 million financing (the Concurrent Financing). On a pro forma, fully diluted basis (using disclosed assumptions), Candid equityholders are expected to own ~57.55% of the combined company, Concurrent Financing investors ~38.80%, and pre-Merger Rallybio equityholders ~3.65%. The Exchange Ratio and ownership outcomes assume a Rallybio valuation of $47.5 million (assuming Rallybio Net Cash of $37.5 million) and a fixed Candid valuation of $750.0 million. The Merger is conditioned on stockholder approvals, customary closing conditions, regulatory clearances including HSR, and satisfaction or waiver of other specified conditions.
Rallybio Corporation files its annual report describing a clinical-stage rare disease pipeline and a planned all‑stock merger with Candid Therapeutics. The deal includes a $505.5 million concurrent financing into Candid and complex exchange ratios that will significantly reshape ownership.
On a pro forma fully diluted basis, Candid equityholders are expected to own about 57.55% of the combined company, Rallybio pre‑merger holders about 3.65%, and concurrent financing investors about 38.80%, subject to net cash and other adjustments. Existing Rallybio holders will also receive contingent value rights tied to future monetization of Rallybio’s legacy assets, including payments from Recursion under a 2025 ENPP1 program sale.
The report highlights lead C5 inhibitor RLYB116, which showed complete and sustained complement inhibition in a 2025 Phase 1 multiple‑ascending‑dose trial, and preclinical iron‑overload antibody RLYB332. Rallybio notes prior collaborations, asset sales, and an ongoing strategic shift toward the Candid autoimmune T‑cell engager platform while winding down certain general and administrative functions.
FMR LLC filed an initial ownership report for Rallybio Corp, disclosing indirect beneficial ownership of 211,798 shares of Common Stock. These shares are held through F-Prime Capital Partners Life Sciences Fund VI LP. The filing records this position as a holding rather than a new purchase or sale.
FMR LLC reports beneficial ownership of 561,798 shares of Rallybio Corp common stock, representing 10.6% of the class. The Schedule 13G/A lists sole dispositive and sole voting power for FMR LLC over these shares and notes certain other persons may have rights to dividends or sale proceeds.
RALLYBIO CORP ownership disclosure: FMR LLC reports beneficial ownership of 372,827 shares of common stock, equal to 7.1% of the class as of 03/02/2026. The filing states FMR LLC has sole voting and dispositive power over these 372,827 shares.
The filing also attributes dispositive power over the same 372,827 shares to Abigail P. Johnson. Signatures are dated 03/05/2026 and an Exhibit 99 is referenced for a 13d-1(k)(1) agreement.